Doximity Raised Guidance and Beat on Revenue on August 6, 2026 — DOCS Jumped 36% Despite a Small EPS Miss

Doximity reported quarterly revenue of $156.6 million on August 6, 2026, up 7.3% year over year and ahead of analyst estimates, alongside adjusted EBITDA of $74.77 million that beat the $69.59 million consensus estimate by roughly 7.4%. The headline move, though, was guidance: Doximity raised its full-year revenue outlook to a range of $671 million to $681 million, up from its prior $664 million to $676 million range and above the roughly $670.3 million analysts had modeled.

The one soft spot in the report was profitability per share: non-GAAP earnings per share of $0.29 came in about 4.2% below analyst consensus, even as EBITDA beat comfortably. That combination — EBITDA ahead of estimates, EPS slightly behind — typically reflects factors below the operating line rather than a deterioration in the underlying business Doximity's revenue and EBITDA figures were describing.

DOCS jumped roughly 36% in the fifteen minutes after the report. A move of that size on a healthcare software platform stock reflects the market weighting the raised full-year guidance and the EBITDA beat far more heavily than the modest EPS miss — guidance raises are read as management's own view of forward demand, and a company raising its outlook while already beating current-quarter estimates is a stronger signal than either fact in isolation.